Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy

Strady, C.; Jaussaud, R.; Béguinot, I.; Lienard, M.; Strady, A.

doi:10.1016/s0264-410x(00)00054-2

Cited by 28 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, vaccination costs against rabies virus can be highly prohibitive and severely limit the usage of this life-saving vaccine. Intradermal regimes of vaccinations have been developed and used in tropical countries in an effort to reduce vaccination costs [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Even though this new vaccination mode may reduce costs, it requires multiple visits to vaccination facilities and skilled practitioners in order to administer the vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…In fact, IMT504 has been demonstrated to be immunostimulatory only in rats, monkeys and humans, with IMT504 being most active in humans [9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Therefore, we decided to perform a pilot study of rabies vaccination in human volunteers.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, 4/5 of these individuals reached levels higher than 30 IU/ml. According to Strady et al [17], these individuals may need a booster only after 5 -10 years as compared to the more frequent booster schedule currently recommended by the WHO. Clearly, these encouraging results are greatly limited by the small number of individuals assayed in this pilot study, and extensive clinical trials should be performed in order to validate the possible use of IMT504 as adjuvant in a new rabies vaccine aimed to reduce economic costs.…”

Section: Discussionmentioning

confidence: 99%

“…This is particularly significant according to the criteria established by the WHO, as the values of IU/ml reached in the group injected with the IMT504-adjuvanted vaccine correspond to individuals with elevated seroconversion. Furthermore, according to the predictive model of Strady et al [17], those individuals reaching titers of 30 IU/ml after vaccination may need a booster only after 5 -10 years as compared to the more frequent booster schedule currently recommended by the WHO.…”

Section: Immunization Of Human Volunteers With Vero Cell Rabies Vaccimentioning

confidence: 99%

See 3 more Smart Citations

IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing

Montaner¹,

Nichilo²,

Rodríguez³

et al. 2012

WJV

View full text Add to dashboard Cite

Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligodeoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat challenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504-adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Immunization Of Human Volunteers With Vero Cell Rabies Vaccimentioning

confidence: 99%

See 2 more Smart Citations

IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing

Montaner¹,

Nichilo²,

Rodríguez³

et al. 2012

WJV

View full text Add to dashboard Cite

show abstract

“…Afterwards, the assessment of the efficacy of rabies vaccination campaigns requires blood sampling of vaccinated animals to measure the respective immune response (Strady et al 2000). The most commonly used techniques for this purpose are the serum neutralizing methods performed on mice or cell culture (King 1966, Atanasiu 1967, Habel 1996.…”

mentioning

confidence: 99%

Rabies neutralizing antibody detection by indirect immunperoxidase serum neutralization assay performed on chicken embryo related cell line

Cardoso¹,

Silva²,

Albas³

et al. 2004

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Detection of Cellular Immunity to Rabies Antigens in Human Vaccinees

et al. 2006

View full text Add to dashboard Cite

A nonradioactive multi-parameter flow cytometry assay was developed to identify antigen-specific lymphocytes in human subjects previously vaccinated against rabies virus and was subsequently compared to the standard tritiated thymidine method. A cell tracking dye, carboxyfluorescein succinimidyl ester, was used in combination with surface label for CD4 and CD8 cells in order to determine the response of lymphocytes to killed rabies virus in an antigen recall assay. The rabies virus-specific lymphocyte response was compared to the humoral immune response in each of ten vaccinated and five non-vaccinated subjects. Lymphocyte responses to rabies virus were observed in all ten vaccinated subjects; some noted as early as 3 days after stimulation while others were not until 7 days after stimulation. There was good agreement between the proliferation index of the CFSE assay and the simulation index of the [3H]thymidine assay (kappa statistic=0.73). An inverse relationship was detected between the level of rabies virus neutralizing antibody (RVNA) and the lymphocyte response to inactivated rabies virus in the vaccinated subjects. The association between cytokines production and level of humoral and cellular response was investigated in four representative subjects. Two vaccinated subjects with high proliferation indices and low RVNA titers produced Th1 type cytokines to rabies virus stimulation, whereas two vaccinated individuals with low proliferation indices and high RVNA titers responses did not produce these cytokines.

show abstract

Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy

Cited by 28 publications

References 15 publications

IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing

IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing

Rabies neutralizing antibody detection by indirect immunperoxidase serum neutralization assay performed on chicken embryo related cell line

Detection of Cellular Immunity to Rabies Antigens in Human Vaccinees

Contact Info

Product

Resources

About